Diabetic Foot Ulcer
Diabetic foot ulcer (DFU) is an open sore or wound in patients with diabetes; they occur in type 1 and type 2 diabetes mellitus. The average duration of diabetes before ulceration is &gt;10 years. The wound is commonly located on the bottom of the foot. A DFU is caused by neuropathic (nerve) and vascular (blood vessel) complications of diabetes. Nerve damage due to diabetes causes altered or complete loss of feeling in the foot and/or leg, known as peripheral neuropathy.
&nbsp;
Diabetic Foot Ulcer Epidemiological Segmentation
The Epidemiological Segmentation of DFU from 2019 to 2032 is segmented as:-
<ul>
<li>Total Prevalent Cases of Diabetic Foot Ulcer</li>
<li>Total Diagnosed Cases of Diabetic Foot Ulcer</li>
<li>Gender-specific Cases of Diabetic Foot Ulcer</li>
<li>Age-Specific Cases of Diabetic Foot Ulcer</li>
<li>Diabetic Foot Ulcer cases by severity/ chronicity of wound</li>
<li>Treated cases of Diabetic Foot Ulcer</li>
</ul>
&nbsp;
Diabetic Foot Ulcer Epidemiology (2021)&nbsp;
<ul>
<li>The total number of Diabetic Foot Ulcer prevalent cases in the 7MM is 6.1 Million</li>
<li>Diabetic Foot Ulcer diagnosed prevalence cases in males were observed to be 1.6 Million cases and in females, it was observed to be 1.1 Million cases.</li>
</ul>
&nbsp;
Diabetic Foot Ulcer Market Drivers
<ul>
<li>Rich emerging pipeline</li>
<li>Development of new treatment modalities</li>
<li>Patients-friendly dosage regimes</li>
</ul>
&nbsp;
Diabetic Foot Ulcer Market Barriers
<ul>
<li>The burden of high cost in DFU treatment</li>
<li>Post-operative challenges in DFU patients</li>
<li>Lack of access to specialists&nbsp;</li>
</ul>
&nbsp;
Diabetic Foot Ulcer Emerging Drugs
The emerging drugs of the DFU market are
<ul>
<li>TTAX01 (Neox Cord 1K)</li>
<li>Engensis (VM202; Donaperminogene Seltoplasmid)</li>
<li>ON101 (WH-1)</li>
<li>Allo-APZ2-DFU (ABCB5 positive MSCs)</li>
<li>Bisphosphocin Nu-3</li>
<li>AUP1602-C</li>
<li>RAPID Biodynamic PRP Haematogel</li>
<li>MBN-101 (Pravibismane)</li>
<li>ExpressGraft (C9T1 Skin Tissue), And many more</li>
</ul>
&nbsp;
Diabetic Foot Ulcer Key Players
<ul>
<li>The key players in the DFU market are</li>
<li>Amniox (TissueTech)</li>
<li>Helixmith</li>
<li>Oneness Biotech</li>
<li>Rheacell (a subsidiary of Ticeba)</li>
<li>Lakewood-Amedex</li>
<li>Aurealis Therapeutics</li>
<li>Biotherapy Services</li>
<li>Microbion Corporation</li>
<li>Mallinckrodt, And many more</li>
</ul>

Diabetic Foot Ulcer Market

Diabetic Foot Ulcer Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.